Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | GAPDH | P04406 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25873876 | 1.00 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL29581997 | 1.00 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL24878603 | 1.00 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL26535891 | 1.00 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL2258922 | 0.98 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31588239 | 0.96 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL17861065 | 0.95 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL24829612 | 0.94 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL23668111 | 0.94 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL21073914 | 0.94 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2647713-B1 | MODIFIED SINGLE-STRAND POLYNUCLEOTIDE | DAIICHI SANKYO CO LTD (JP) | 2018-02-21 | — | — | EP | disclosed |
| US-9885036-B2 | Double-stranded polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| EP-2305805-B1 | DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-8987226-B2 | Modified single-stranded polynucleotides | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2647713-A1 | MODIFIED SINGLE-STRAND POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130253038-A1 | Modified Single-Stranded Polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-26 | — | — | US | disclosed |
| US-20130018085-A1 | iRNA Agents Targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2013-01-17 | — | — | US | disclosed |
| US-8293719-B2 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2495323-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | Daiichi Sankyo Company, Limited (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120045461-A1 | Compositions and Methods for Inducing an Immune Response in a Mammal and Methods of Avoiding an Immune Response to Oligonucleotide Agents Such as Short Interfering RNAs | ALNYLAM PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20110224282-A1 | iRNA Agents Targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-2365077-A1 | iRNA agents targeting VEGF | Alnylam Pharmaceuticals, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-8003619-B2 | Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED | 2011-06-23 | — | — | US | disclosed |
| US-7947659-B2 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2305805-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | Daiichi Sankyo Company, Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-7919473-B2 | IRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20060217330-A1 | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs | BANK OF AMERICA, N.A. | 2006-09-28 | — | — | US | disclosed |
| US-20060094032-A1 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094032-A1 | iRNA agents targeting VEGF | KDR, FLT4, SNRPE | TYMP 1464/4885PRMT6 1300/4885PRKAG1 926/4885 |
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | POLM, POLN, PNKP | TYMP 15/4885PRMT6 3299/4885PRKAG1 2785/4885 |
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | NSUN2, TRDMT1, POLRMT | TYMP 151/4885PRMT6 574/4885PRKAG1 1384/4885 |
| US-20130018085-A1 | iRNA Agents Targeting VEGF | KDR, FLT4, SNRPE | TYMP 1464/4885PRMT6 1300/4885PRKAG1 926/4885 |
| US-20110224282-A1 | iRNA Agents Targeting VEGF | KDR, FLT4, SNRPE | TYMP 1464/4885PRMT6 1300/4885PRKAG1 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.